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Summary The expression of interleukin 10 (IL-10) mRNA in human malignant melanoma was investigated
by reverse transcriptase polymerase chain reaction analysis. Selective expression of IL-10 mRNA in tissues of
primary melanomas and melanoma metastases was found in comparison with normal skin. In addition, strong
expression of IL-10 mRNA and of biologically active IL-10 was detected in 3 out of 13 melanoma cell lines.
Normal melanocytes consistently expressed low levels of IL-10 mRNA but did not produce detectable IL-10
protein, nor did keratinocytes or fibroblasts. The production of biologically active IL-10 by melanoma cell
lines suggests that IL-10 mRNA in melanoma lesions may derive at least in part from the tumour cells
themselves. Tumour-infiltrating cells, however, could also be a source of IL-10 in melanoma tissues. The
presence of IL-10 in melanoma lesions may contribute to the postulated 'paralysis' of an anti-melanoma
immune response.
The immunogenicity of human malignant melanoma is well
documented (Topalian et al., 1989). Nevertheless, melanomas
obviously escape immune surveillance (Rosenberg, 1991). The
failure of the immune system to effectively respond to and to
reject the tumour indicates mechanisms 'paralysing' tumour-
specific responses (Russel, 1990; Hock et al., 1993). One of
the possibilities is the secretion of immunosuppressive factors
either by tumour-infiltrating cells and/or by the tumour cells
themselves. A candidate for such a factor in humans is
interleukin 10 (IL-10), which has been shown to dampen the
immune response by down-regulating the secretion of several
cytokines by T cells and monocytes (Vieira et al., 1991; De
Waal Malefyt et al., 1991a; Ralph et al., 1992) and by
reducing antigen-specific activation of T lymphocytes by
diminishing the antigen-presenting capacity ofmonocytes (De
Waal Malefyt et al., 1991b; Tosato & Taga, 1992).
Therefore, we investigated the expression of IL-10 mRNA
in tissue specimens of primary malignant melanomas and
melanoma metastases as compared with normal skin using
reverse transcriptase polymerase chain reaction (RT-PCR)
analysis. This approach has already been shown to be
valuable for the evaluation of profiles of cytokine expression
in tissues, e.g. in leprosy lesions (Yamamura et al., 1991). In
addition, we screened established human melanoma cell lines
as well as normal melanocytes, keratinocytes and fibroblasts,
the major cellular constituents of normal skin, for expression
of IL-10 mRNA and secretion of IL-10 protein.
Materials and methods
Specimens
Tumour specimens were obtained from five patients with
histologically verified primary malignant melanoma and from
three patients with melanoma metastases after informed con-
sent and consisted predominantly of central tumour without
dermis. Normal skin was obtained at the same time from a
site 3 cm distant from the primary tumour. Tissue specimens
were snap frozen in liquid nitrogen immediately after surgical
removal, and stored at -80°C.
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Cell lines
Thirteen established melanoma cell lines (Bro, A375, NKI-4,
SKMel-28, MeWo, IGR-39, Mel-57, 0-Mel-II, Mel-2a,
SKMel-13, SKMel-19, IGR-37 and M5) (Eberle et al., 1993,
and references therein) were grown in Dulbecco's modified
Eagle medium (DMEM) supplemented with 10% fetal calf
serum, 2mM glutamin and antibiotics.
Melanocytes (StNM-1, StNM-7, StNM-8, Lei-1, Mel-4,
Mel-5 and Mel-6) and keratinocytes were obtained from
trypsin-digested foreskin and cultured according to standard
protocols in selective media. Keratinocytes were maintained
in MCDB 153 (Biochrom, Berlin, Germany) supplemented
with 10 ng ml-l epidermal growth factor (Sigma, Deisen-
hofen, Germany), 0.4% (v/v) bovine pituitary extract
(Clonetics, San Diego, CA, USA), 5 fg ml-l insulin (Sigma)
and 50IM hydrocorticosne (Serva, Heidelberg, Germany).
Melanocytes were cultured in the same medium as
keratinocytes without epidermal growth factor, additionally
supplemented with 2 mM Ca2+, 2 ng ml-' basic fibroblast
growth factor (Boehringer Mannheim, Germany), 10 igml1'
transferrin (Sigma) and 1 nM cholera toxin (Calbiochem, La
Jolla, CA, USA). Fibroblasts were grown from dermis in
DMEM with 10% fetal calf serum. When preconfluent, cells
were trypsinised and snap-frozen pellets were stored at
-800C.
RT-PCR analysis
RT-PCR analysis was performed as previously described
(Uberla et al., 1991). Briefly, tissue samples or cell pellets
were homogenised and total cellular RNA was isolated using
the guanidium thiocyanate/caesium chloride method. A 3fig
aliquot of total cellular RNA was reverse transcribed using
random hexanucleotide as primer. A complementary DNA
(cDNA) equivalent of 0.5 ng of RNA was amplified in a
50ftl reaction mix during 35 cycles (1 min denaturation at
94C, 1 min annealing at 60C, 1 min extension at 72°C).
Each experiment included a positive control [cDNA of IL-2-
stimulated lymphokine activated killer (LAK) cells] and a
negative control consisting either of reaction mix without
cDNA or of sample RNA that had not been reverse trans-
cribed. For comparison of IL-10 mRNA levels in different
tissue specimens, cDNAs were first adjusted to equal concen-
trations of P-actin by competitive PCR as recently described
(IJberla et al., 1991). Briefly, serial 10-fold and subsequently
2-fold dilutions of cDNA were amplified in the presence of a
fixed amount of P-actin control fragment, in order to deter-
mine exactly the amount of cDNA required to achieve equal
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band intensities for both fragments. The so-equalised cDNAs
were then analysed for IL-10 mRNA content. Specificity of
amplification products was verified by restriction analysis
with two enzymes indicative for the expected amplified
sequence (data not shown). Electrophoresis of 20 jil of PCR
reaction or digestion product on 1.5% agarose gel containing
ethidium bromide was performed to evaluate amplification
and size of the generated fragments in comparison with the
KB DNA ladder (Gibco/BRL, Gaithersburg, MD, USA).
Primer sequences for ,-actin (positions 103-122 and
642-619) and IL-10 (positions 283-309 and 608-634) were
taken from Yamamura et al. (1991) and crossed intron-exon
boundaries in genomic DNA.
Assaysfor IL-1O reactivity
Melanoma cells and melanocytes were incubated for 48 h at
1 x 106 cells ml-' and supernatants (SNs) were collected. SNs
were assayed for IL-10 activity by an IL-10 enzyme-linked
immunosorbent assay (ELISA) kit according to the supplier's
recommendations (Cytoscreen, BioSource International,
Camarillo, CA, USA). The lower detection limit of the
ELISA was 18 pg ml' for human IL-10. In addition, IL-10
activity was tested in the murine D36 mast cell proliferation
assay (Schlaak et al., 1993). Functionally, human IL-10 has
been shown to possess the same biological activity as murine
IL-10 when tested on murine cell targets (Vieira et al., 1991).
Briefly, aliquots of the SNs and serial 2-fold dilutions were
added to microtitre plates containing 1 x 103 D36 cells per
well and murine IL-4 (8 units ml-') in a final volume of
200jil. Cultures were incubated for 24 h at 37°C, pulse
labelled for another 18 h with 0.1IlCi per well [3H]thymidine
(5 Ci mmol
' specific activity) and harvested on glass fibre
filters for measurement of [3H]thymidine uptake in a scintilla-
tion counter. One unit per ml of IL-1O activity was defined as
the reciprocal of SN dilution required for half-maximal pro-
liferation. In order to confirm specificity of bioactivity, D36
cell proliferation was determined in the presence of the
neutralising rat anti-human IL-10 monoclonal antibody
JES3-19F1 (IgG 2a) (2.5;Lg ml-') (De Waal Malefyt et al.,
1991b) and an isotype-matched control antibody
(2.5 tLg ml1 '). JES3-19F1, in concentrations up to
0.1 fg ml-', completely blocked biological activity of
5 units ml-' recombinant human IL-IO.
Results
RT-PCR analysis ofIL-JO mRNA expression in tissue
specimens
To investigate the expression of IL-10 mRNA in small speci-
mens of human primary melanoma and melanoma metas-
tases, we extracted total cellular mRNA from tissue speci-
mens, and reverse transcribed it to cDNA. To provide mean-
ingful comparison between different tissue samples, cDNAs
were normalised to P-actin PCR product by competitive
amplification of the cDNAs with a P-actin control fragment
(see Figure 1). These standardised cDNA samples were
analysed for IL-10 transcripts using IL-10-specific primers.
Four out of five primary melanomas expressed IL-10
mRNA, whereas four out of five matched normal skin sam-
ples showed no IL-10 transcripts at all, and one skin sample
barely expressed IL-10 mRNA (Figure 1). In addition, all
three melanoma metastases analysed clearly expressed IL-10
mRNA.
Expression ofIL-JO mRNA and secretion ofIL-JO protein in
cell cultures
To determine whether melanoma cells themselves express
IL-10 mRNA and may be a source of IL-10 mRNA observed
in melanoma tissues, we screened 13 human melanoma cell
lines for gene expression of IL-10 by RT-PCR analysis as
compared with normal melanocytes, keratinocytes and fibro-
blasts. As illustrated in Figure 2a, 3 out of 13 melanoma cell
lines strongly expressed mRNA of IL-10, one showed
moderate and three weak expression, whereas six cell lines
were negative. In melanocyte cultures from seven different
donors, weak but clearly detectable levels of IL-10 mRNA
were consistently observed (Figure 2b), while fibroblasts and
keratinocytes (cultures from two different donors) did not
express IL-10 mRNA (data not shown). The amounts of
cDNA analysed were similar in various samples and also
between different cell types, as could be shown by amplifica-
tion of,-actin mRNA (Figure 2). We next analysed SNs of
these 13 melanoma cell lines and seven melanocyte cultures
for IL-10 reactivity. The level of IL-10 mRNA detected in
melanoma cell lines by RT-PCR correlated with the amount
of IL-10 found in SNs, ranging form 0.57 ng ml-' to
3.40 ng ml-' IL-10 (Table I). Only cell line A375 which had
shown moderate expression of IL-10 mRNA did not secrete
measurable levels of IL-10 protein, nor did the other three
cell lines with weak IL-10 transcripts. SNs of all seven
melanocyte cultures tested did not contain measurable IL-10
protein. To confirm biological activity of melanoma cell-
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Figure 1 Expression of IL-10 mRNA in primary malignant
melanoma (PM), melanoma metastases (MM) and normal skin
(NS). The cDNAs derived from lesions were normalized to P-
actin PCR product by competitive amplification with a P-actin
control fragment (c.f.) and then analysed for IL-10 transcripts
(see arrow) using IL-10-specific oligonucleotide primers.
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Figure 2 Expression of IL-10 mRNA (see arrow) in human
melanoma cell lines (a) (lanes 2-16: Bro, A375, NKI-4, SKMel-
28, MeWo, IGR-39, Mel-57, 0-Mel-II, Mel-2a, SKMel-13,
SKMel-19, IGR-37, M5, LAK, negative control) and melanocyte
cultures (b) (lanes 2-7: StNM-l, StNM-7, StNM-8, Lei-l, Mel-4,
Mel-5, Mel-6, LAK, negative control). Lane I in each case shows
the KB DNA ladder. The amount of cDNA analysed was similar
in different samples and cell types as shown by PCR
amplification of P-actin mRNA.
Table I Expression of IL-10 reactivity in human melanoma cell
lines
Melanoma cell line ELISA (ngml-') Bioassay (units ml-')
A375 0 0
NKI-4 2.070 3
IGR-39 0.570 1,5
SKMel-19 3.400 6
IL-10 activity secreted in culture media per 106 cells ml- and 48 h,
as determined by (a) an IL-10-specific ELISA and by (b) the D36
mast cell proliferation assay. Results are given as average of three
experiments; s.d. values were less than 10%.
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derived IL-10, culture SNs were tested in the D36 assay. SNs
of the three melanoma lines that had been found positive in
the IL-10 ELISA contained activities which varied between 1
and 8 units ml-', and could be specifically neutralised by an
anti-IL-10 monoclonal antibody.
Discussion
The results presented here demonstrate that mRNA for IL-10
is found in tissues of primary tumours and metastases but
not in adjacent normal skin of patients with malignant
melanoma. The PCR technique used does not enable us to
distinguish which cells in the tumour tissue are producing
IL-10 mRNA: it may originate either from infiltrating cells
known to be able to produce IL-10 in humans, e.g. B cells, T
cells and monocytes (Vieira et al., 1991; De Waal Malefyt et
al., 1991a; Yssel et al., 1992; Del Prete et al., 1993) and/or
from melanoma cells themselves. The mere presence of lym-
phocytic infiltrates in skin lesions does not necessarily signify
IL-10 expression, as has been shown for epithelial tumours
(Yamamura et al., 1993). The present finding, that metastatic
lesions which normally show less inflammatory response than
primary melanomas (Payan et al., 1970) expressed levels of
IL-10 mRNA similar to the primary tumours, together with
the fact that several melanoma cell lines constitutively
secreted IL-10 rather argues for the possibility that IL-10 in
melanoma tissue may be produced by the tumour cells them-
selves. However, to characterise unequivocally IL-10-
expressing cells in the melanoma tissues either in situ hyb-
ridisation or immunohistochemistry has to be applied in
further investigations. Melanocytes, the benign counterparts
of melanoma cells, weakly expressed IL-10 mRNA but did
not produce detectable IL-10 protein, nor did fibroblasts and
keratinocytes. In one out of five normal skin samples
examined in the present study, IL-10 mRNA was detected. In
support of these results, constitutive expression of IL-10
mRNA has been found occasionally in unstimulated murine
skin and reproducibly in hapten-stimulated skin samples
(Enk & Katz, 1992). Accordingly, hapten-stimulated murine
keratinocytes expressed IL-10 mRNA and protein. Possibly,
appropriate stimulation may lead to IL-10 expression by
human keratinocytes as well.
Interestingly, selective expresssion of IL-10 mRNA has
also been found in ovarian tumours but not in normal
ovaries and ovarian tumour cell lines (Pisa et al., 1992).
Moreover, our results are in line with recent published PCR
data on the comparison of cytokine profiles in another
malignant tumour of the skin, namely basal cell carcinoma,
to that of seborrhoeic keratosis, a benign hyperplasia of
epidermis (Yamamura et al., 1993). The authors noted pro-
minent mRNA expression of IL4 and IL-10 in carcinoma
specimens, but of IL-2 and interferon gamma in irritated
seborrhoeic keratosis. Most recently, the constitutive produc-
tion of IL-10 mRNA and protein by several human car-
cinoma cell lines has been reported (Gastl et al., 1993). IL-10
was produced predominantly by epithelial cancer cell lines
such as colon carcinoma, malignant melanoma and renal cell
carcinoma. While these studies were restricted to established
cell lines we could additionally demonstrate expression of
IL-10 in tissues of primary and metastatic melanomas. IL-10
is a pleiotropic cytokine, and there is accumulating evidence
from in vitro systems that IL-10 may play an important role
not only in the regulation of T cell responses, but also as an
anti-inflammatory mediator in vivo (Richter et al., 1993). It is
therefore intriguing to speculate that IL-10 suppresses anti-
tumour immune responses and thereby facilitates tumour
growth and development. IL-10 in human tumours could act,
for example, by reduction of cell-mediated cytotoxicity and
antigen presentation by monocytes (De Waal Malefyt et al.,
1991b), or by down-regulation of tumour necrosis factor oc
and/or interferon gamma production, two tumoricidal prod-
ucts of monocytes and T cells (De Waal Malefyt et al.,
1991a; Ralph et al., 1992; Tosato & Taga, 1992; Del Prete et
al., 1993).
Most recently, production of IL-10 mRNA and IL-10
protein could be detected in situ in AIDS lymphomas (Emilie
et al., 1992). Expression of IL-10 was associated with the
presence of Epstein-Barr virus in lymphomatous cells.
Human IL-10 exhibits extensive sequence homology to a
previously uncharacterised open reading frame in the Ep-
stein-Barr virus genome, BCRF-I (Vieira et al., 1991). The
protein product of BCRF-1, designated viral IL-10, shares
most properties with IL-10, including cytokine synthesis-
inhibtory activity on T cells (Hsu et al., 1990) and suppres-
sion of antigen-specific proliferative T-cell response as a
result of down-regulation of class II major histocompatibility
complex molecules on monocytes (De Waal Malefyt et al.,
1991b). The possibility that messages detected in the PCR
analysis of melanoma lesions may result from BCRF-I ex-
pression is ruled out, since PCR primers were designed to
specifically amplify mRNA of human IL-10 but not mRNA
of viral IL-10 (Hsu et al., 1990; Vieira et al., 1991).
Our present data demonstrate the selective expression of
IL-10 mRNA in human melanoma tissue. In addition, prod-
uteion of biologically active IL-10 has been found in some
melanoma cell lines. There are several reports that melanoma
cell lines express mRNAs and also proteins for various
cytokines, e.g. IL-1, IL-6, IL-8, IL-10, tumour necrosis factor
a and granulocyte colony-stimulating factor (Colombo et al.,
1992, and reviewed therein; Gastl et al., 1993). These and
other cytokines are likely to be involved in the immune
response to cancer. At this time it is unclear what the net
effects of multiple cytokines are on the outcome of the host
response to tumour. For unknown reasons some (about
20%) but not all melanoma patients respond to IL-2
immunotherapy (Rosenberg, 1991). The presence of IL-10 in
melanoma lesions, whatever its source may be, might in-
fluence the immune response to this tumour. The role of
IL-10 as a possible prognostic marker for successful
immunotherapy remains to be investigated.
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